ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Management and the future

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jul 14, 2022 4:51pm

94 Views

Post# 34825274

RE:RE:RE:RE:RE:RE:RE:Management and the future

No, the point is that we have 6-12 months more to wait to find out if PMN has what they seem to think they have. If they do, then we, as shareholders, will benefit. If not, then the gamble is lost. And that's all this really is. A gamble.

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”